Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRIUS-LN phase 3 trial of ianalumab added to standard-of-care in active lupus nephritis
2023-508559-37-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing Ianalumab + standard-of-care with Placebo + standard-of-care (2 arms). Primary endpoint: Stable complete renal response at Week 72. Planned start Jul 2022; status: authorised.
02
Drugs
ianalumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-508559-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508559-37-00.